Younger patients with primary Sjögren’s syndrome are more likely to have salivary IgG anti-muscarinic acetylcholine receptor type 3 antibodies

Jayakanthan, K.; Janardana, Ramya; Mandal, Santosh K.; Sandhya, Pulukool; Mahasampath, Gowri; Danda, Debashish

doi:10.1007/s10067-016-3186-0

Cited by 9 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite this, we observed a relatively high prevalence of antibodies binding to MR5 in the Ro + SS group, and patients with this reactivity displayed more severe SS by multiple measures. Both of these features, namely association with anti-Ro reactivity and more severe disease, have been reported for patients with SS having serum antibody reactivity to MR3 35–39. We noted that the vast majority of patients with MR5-binding antibodies also produced serum autoantibodies to both Ro52 and Ro60, and this patient group has been shown to have increased prevalence of abnormal ocular surface staining, positive focus scores, ANAs ≥1:320, positive La antibodies, rheumatoid factor and elevated IgG 25.…”

Section: Discussionsupporting

confidence: 64%

Autoantibodies identify primary Sjögren’s syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B

et al. 2023

View full text Add to dashboard Cite

ObjectiveIdentify autoantibodies in anti-Ro/SS-A negative primary Sjögren’s syndrome (SS).MethodsThis is a proof-of-concept, case-control study of SS, healthy (HC) and other disease (OD) controls. A discovery dataset of plasma samples (n=30 SS, n=15 HC) was tested on human proteome arrays containing 19 500 proteins. A validation dataset of plasma and stimulated parotid saliva from additional SS cases (n=46 anti-Ro+, n=50 anti-Ro–), HC (n=42) and OD (n=54) was tested on custom arrays containing 74 proteins. For each protein, the mean+3 SD of the HC value defined the positivity threshold. Differences from HC were determined by Fisher’s exact test and random forest machine learning using 2/3 of the validation dataset for training and 1/3 for testing. Applicability of the results was explored in an independent rheumatology practice cohort (n=38 Ro+, n=36 Ro–, n=10 HC). Relationships among antigens were explored using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) interactome analysis.ResultsRo+SS parotid saliva contained autoantibodies binding to Ro60, Ro52, La/SS-B and muscarinic receptor 5. SS plasma contained 12 novel autoantibody specificities, 11 of which were detected in both the discovery and validation datasets. Binding to ≥1 of the novel antigens identified 54% of Ro–SS and 37% of Ro+SS cases, with 100% specificity in both groups. Machine learning identified 30 novel specificities showing receiver operating characteristic area under the curve of 0.79 (95% CI 0.64 to 0.93) for identifying Ro–SS. Sera from Ro–cases of an independent cohort bound 17 of the non-canonical antigens. Antigenic targets in both Ro+and Ro–SS were part of leukaemia cell, ubiquitin conjugation and antiviral defence pathways.ConclusionWe identified antigenic targets of the autoantibody response in SS that may be useful for identifying up to half of Ro seronegative SS cases.

show abstract

Section: Discussionsupporting

confidence: 64%

Autoantibodies identify primary Sjögren’s syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B

et al. 2023

View full text Add to dashboard Cite

show abstract

“…20 To date, anti-acetylcholine type 3 receptor (M3R) antibodies have been shown to be more common in younger patients and patients with hyperglobulinemia. 21 According to the previous research, patients with the early-onset phenotype of pSS have a higher incidence of lymphadenopathy, RF and anti-SSA antibodies. 8,22 Although Tishler et al reported more frequent organ involvement in the form of parotid gland enlargement, joint involvement and central nervous system involvement in patients with early-onset pSS, these results were not statistically significant.…”

Section: Discussionmentioning

confidence: 95%

Differences in clinical phenotypes of primary Sjögren’s syndrome depending on early or late onset

Sebastian

Madej

Sebastian³

et al. 2021

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Previous research suggests that systemic involvement in primary Sjögren's syndrome (pSS) is a marker of disease prognosis.Objectives. To evaluate pSS disease activity and the clinical phenotype of pSS patients depending on the age at diagnosis with long-term follow-up. Materials and methods.The study group consisted of patients diagnosed with pSS based on the 2016 pSS classification criteria.Results. The study group consisted of 46 patients with early-onset pSS (≤35 years of age) and 32 patients with late-onset pSS (≥65 years of age). The study group was identified from a total of 228 patients diagnosed with pSS. There were no differences regarding the frequency of eye and mouth dryness, focus score (FS) ≥1 or anti-SSA/SSB antibodies depending on age. Rheumatoid factor (RF) was more common among older patients (p > 0.05). In the overall assessment of disease activity using European League Against Rheumatism (EULAR) Sjögren Syndrome Disease Activity Index (ESSDAI), no differences related to age were observed on the first and last visit (after 36 months on average). Lymphadenopathy and changes in the hematology domain (p < 0.05) were more common in patients with the early-onset phenotype. Changes in the lungs and musculoskeletal system occurred regardless of age.Conclusions. Patients with early-onset pSS differ from those with late-onset pSS in terms of higher incidence of peripheral lymphadenopathy and cytopenia. The involvement of lung tissue and joints as well as dryness symptoms are common in pSS regardless of age. The RF plays a role in the pathomechanism of pSS development.

show abstract

“…Muscarinic type 3 receptor (M3R) is highly expressed in exocrine glands and regulates the secretion of salivary acinar cells (Sumida T, Iizuka M, Asashima H, et al, 2012). Jayakanthan found that saliva anti-M3R IgG antibodies have high specificity for the detection of SS and are more easily detectable in younger patients and hyperglobulinemia (Jayakanthan K, Ramya J, Mandal S K, et al, 2016). The results of Mona showed that saliva anti-M3R levels in SS patients were 3.59 times higher than in healthy people (Mona M, Mondello S, Hyon J Y, et al, 2021).…”

Section: Saliva Autoantibodiesmentioning

confidence: 99%

Salivary Biomarkers in the Diagnosis of Sjogren’s Syndrome: A Review of Current Research Progress

Zheng

Guan

2023

JIMR

View full text Add to dashboard Cite

Saliva contains a variety of biomarkers, which are closely related to the occurrence, progression, diagnosis and treatment of oral and systemic diseases. Currently, the diagnosis of Sjögren’s syndrome (SS) still relies on invasive salivary gland biopsy procedures and serum Ro-52/SSA and La/SSB testing, which often makes early diagnosis extremely difficult, so screening for specific saliva biomarkers is extremely beneficial in the diagnosis and individualized treatment of Sjögren’s syndrome. This article elaborates the research progress of Sjogren’s syndrome-related biomarkers in saliva, in order to provide new methods and ideas for the early diagnosis of Sjogren’s syndrome.

show abstract

Younger patients with primary Sjögren’s syndrome are more likely to have salivary IgG anti-muscarinic acetylcholine receptor type 3 antibodies

Cited by 9 publications

References 21 publications

Autoantibodies identify primary Sjögren’s syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B

Autoantibodies identify primary Sjögren’s syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B

Differences in clinical phenotypes of primary Sjögren’s syndrome depending on early or late onset

Salivary Biomarkers in the Diagnosis of Sjogren’s Syndrome: A Review of Current Research Progress

Contact Info

Product

Resources

About